Biotech Stock Index

1602

Rita.

RITA NEWS: La Jolla Pharmaceuticals Removed from Rita Biotech Stock Index Following Delisting From Nasdaq

March 5, 01:00 PM

As of March 4th, 2010, La Jolla Pharmaceuticals (LJPC) is no longer being tracked as part of the Rita Biotech Stock Index. The company delisted from Nasdaq following a failed merger attempt with Adamis Pharmaceuticals Corporation. Please view the press release for more information on this delisting.

Cardium Announces Appexium(Tm), A New Weight Loss Management Dietary Supplement to Expand Medpodium's Healthy Lifestyle Product Initiative

Cardium Therapeutics, September 9, 09:00 AM

AVI BioPharma Issued U.S. Patent Providing Key Coverage of RNA-Based Therapeutics as Antibacterial Agents

AVI BioPharma, Inc., September 8, 10:30 AM

BioMimetic Therapeutics Premarket Approval Application (PMA) Remains on Track

BioMimetic Therapeutics, September 8, 08:11 AM

Antisoma’s Phase III Trial of AS1413 Completes Patient Enrolment

Antisoma, September 8, 07:55 AM

EntreMed Secures $5.1 Million in Registered Direct Offering and Enters into Agreement for Rights to License ENMD-2076 in China

EntreMed, Inc., September 8, 07:50 AM

Exelixis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Exelixis Inc., September 7, 09:22 AM

CytRx Initiates Phase 2 Clinical Trial with Bafetinib in Advanced Prostate Cancer

CytRx Corporation, September 7, 08:37 AM

New Patents Expand Coverage for Imaging and Therapeutic Applications of Peregrine's Phospholipid-Targeting Technologies

Peregrine Pharmaceuticals, September 7, 08:33 AM

Covalon Enters Into Employment Agreement with CEO and Grants Stock Options

Covalon Technologies, September 3, 10:54 AM

Celldex Therapeutics Regains Worldwide Rights to Rindopepimut (CDX-110)

Celldex Therapeutics, September 3, 09:52 AM

Agennix Ag Announces Data From Talactoferrin Randomized, Double-Blind, Placebo-Controlled Phase Ii Trial In Severe Sepsis Presented At The Sepsis 2010 International Symposium

Agennix AG, September 3, 09:44 AM

Oncolytics Biotech® Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute

Oncolytics, September 3, 08:37 AM

MorphoSys Initiates Program Against Drug-Resistant MRSA Infections

MorphoSys , September 2, 08:46 AM

Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Agensys, an Affiliate of Astellas

Seattle Genetics, September 2, 08:33 AM

StemCells, Inc.'s Technology Used to Create First Genetically Engineered Rat Derived From Rat Embryonic Stem Cells

StemCells, Inc., September 1, 02:16 PM

NIAID Grant to Fund Dynavax Research on Hepatitis B Vaccination and Individual Variations in Human Responsiveness

Dynavax, August 31, 02:31 PM

Pluristem’s Placenta Derived Cells Chosen by European Commission’s Seventh Framework Program (FP7) Study for Treatment of Diastolic Heart Failure (DHF) in Type 2 Diabetic Patients

Pluristem Therapeutics, August 30, 08:28 AM

Advanced Life Sciences' Journal Publication Highlights Powerful Chemistry Platform

Advanced Life Sciences, August 30, 08:26 AM

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment

Idera Pharmaceuticals, August 27, 11:07 AM

AVI BioPharma Announces Positive Results Against Human Pandemic H1N1 Influenza Virus in Preclinical Studies of AVI-7100

AVI BioPharma, Inc., August 24, 12:44 PM

Comments (0) Add a Comment
Sort by date

Number of comments per page

In order to leave comments, please log in.

© 2000-2010 Landes Bioscience. All rights reserved.